

( (S (NP-SBJ Genentech Inc.)
     (VP said
         (SBAR 0
               (S (NP-SBJ third-quarter profit)
                  (VP (ADVP more than) 
                      doubled
                      (PP-DIR to
			      (NP (NP (QP $ 11.4 million) *U*)
				  , or
				  (NP (NP 13 cents)
				      (NP-ADV a share))
				  ,))
                      (PP-DIR from
			      (NP (NP a depressed 1988 third-quarter performance)
				  (PP of
				      (NP (NP (QP $ 5.3 million) *U*)
					  , or
					  (NP (NP six cents)
					      (NP-ADV a share))))))))))
     .))
( (S (NP-SBJ Revenue)
     (VP rose
         (NP-EXT 23 %)
         (PP-DIR to
		 (NP (QP $ 100 million) *U*))
         (PP-DIR from
		 (NP (QP $ 81.6 million) *U*)))
     .))
( (S (NP-SBJ Net product sales)
     (VP accounted
         (PP-CLR for
		 (NP (QP $ 76 million) *U*))
	 ,
	 (ADVP up 
	       (PP from
		   (NP (QP $ 57.5 million) *U*)
		   (ADVP-TMP (NP a year)
			     earlier))))
     .))
( (S (NP-SBJ (NP Sales)
             (PP of
                 (NP the heart drug TPA)))
     (VP were
         (NP-PRD (NP (QP $ 43.6 million) *U*)
                 ,
                 (ADJP better 
                       (PP than
                           (NP (NP (NP last year 's)
                                   depressed third period)
                               (SBAR (WHADVP-1 when)
                                     (S (NP-SBJ the company)
                                        (VP sold
                                            (NP (NP (QP just $ 29.1 million) *U*) 
                                                (PP of
                                                    (NP the drug)))
					    (ADVP-TMP *T*-1)))))))))
     .))
( (S But
     (NP-SBJ TPA sales)
     (VP fell
         (PP-DIR below
		 (NP (NP levels)
		     (PP for
			 (NP (NP (NP this year 's)
				 (ADJP first and second)
				 quarter sales)
			     (PP of
				 (NP (QP $ 48 million) *U*))))))
	 ,
	 (S-ADV (NP-SBJ *)
		(VP cooling
		    (NP investors))))
     .))
( (S (NP-SBJ Genentech stock)
     (VP fell
         (NP-EXT 12.5 cents)
         (PP-LOC in 
		 (NP (NP trading)
		     (NP-TMP yesterday)
		     (PP-LOC on
			     (NP the New York Stock Exchange))))
         (PP-DIR to
		 (NP $ 20.125 *U*)))
     .))
( (S (PP-TMP In
	     (NP the nine months))
     ,
     (NP-SBJ net income)
     (VP slid
         (NP-ADV 21 %)
         (PP-DIR to
		 (NP (NP (QP $ 28.4 million) *U*)
		     , or
		     (NP (NP 33 cents)
			 (NP-ADV a share))
		     ,))
         (PP-DIR from
		 (NP (NP (QP $ 36 million) *U*)
		     , or
		     (NP (NP 42 cents)
			 (NP-ADV a share)))))
     .))
( (S (NP-SBJ Revenues)
     (VP climbed
         (NP-EXT 18 %)
         (PP-DIR to
		 (NP (QP $ 289 million) *U*))
         (PP-DIR from
		 (NP (QP $ 245.3 million) *U*)))
     .))
( (SINV ``
	(S-TPC-2 (NP-SBJ-1 We)
		 (VP continue
		     (S (NP-SBJ *-1)
			(VP to
			    (VP be
				(PP on
				    (NP target))
				(PP-PRD for ...
					(S-NOM (NP-SBJ *)
					       (VP increasing
						   (NP TPA sales)
						   (NP (NP 20 %)
						       (PP to
							   (NP 25 %))))
					       (NP this year))))))))
	, ''
	(VP said
	    (S *T*-2))
	(NP-SBJ founder and Chief Executive Officer Robert Swanson)
	.))
( (S But
     (NP-SBJ some analysts)
     (VP remain
         (ADJP-PRD sour
                   (PP on
                       (NP the company))))
     .))
( (S ``
     (NP-SBJ TPA sales)
     (VP are
         (ADVP-PRD down)
	 (NP-TMP (NP quarter) 
		 (PP to
		     (NP quarter))))
     .))
( (S (S (NP-SBJ Expenses)
        (VP are
            (ADJP-PRD flat)))
     and
     (S (NP-SBJ that)
        (VP 's
            (NP-PRD a good sign)))
     .))
( (S (NP-SBJ There)
     (VP 's
         (NP-PRD (NP contract revenue)
                 (PP from
                     (NP -LCB- limited research and development -RCB- partnerships))))
     .))
( (SINV (S-TPC-1 But
		 (NP-SBJ I)
		 (ADVP still)
		 (VP think
		     (SBAR 0
			   (S (NP-SBJ the fundamentals)
			      (VP are
				  (ADJP-PRD poor))))))
	, ''
	(VP said
	    (S *T*-1))
	(NP-SBJ (NP Denise Gilbert)
		,
		(NP (NP an analyst)
		    (PP with
			(NP (NP Montgomery Securities)
			    (PP-LOC in
				    (NP San Francisco))))))
	.))
( (S (NP-SBJ Genentech)
     (VP faces
         (NP (NP competition)
             (PP-LOC in
		     (NP the cardiac-drug market))
             (PP from
                 (NP (NP (NP SmithKline Beecham PLC 's)
			 heart drug Eminase)
                     ,
                     (VP expected
                         (S (NP-SBJ *)
                            (VP to
                                (VP receive
                                    (NP market approval)
				    (ADVP-TMP shortly)))))))))
     .))
( (S (S-TPC-2 And
	      (NP-SBJ-1 Genentech)
	      (VP is n't
		  (ADJP-PRD likely
			    (S (NP-SBJ *-1)
			       (VP to
				   (VP have
				       (S (NP-SBJ any new products)
					  (ADJP-PRD ready
						    (PP for
							(NP market))))
				       (PP-TMP until
					       (NP (ADVP at least)
						   1992))))))))
     ,
     (NP-SBJ Ms. Gilbert)
     (VP added
	 (SBAR 0
	       (S *T*-2)))
     .))
( (S ``
     (S-TPC-1 (S (NP-SBJ (NP The company 's)
			 stock)
		 (VP is
		     (VP trading
			 (PP-CLR at
				 (NP (QP 40 times)
				     (NP next year 's)
				     numbers)))))
	      , and
	      (S (NP-SBJ that)
		 (VP 's
		     (ADJP-PRD too much))))
     , ''
     (NP-SBJ she)
     (VP said
	 (S *T*-1))
     .))
( (S (S-TPC-1 (PP On
		  (NP the plus side))
	      ,
	      (NP-SBJ Genentech)
	      (VP is
		  (VP benefiting
		      (PP-CLR from
			      (NP (NP (NP a lower tax rate)
				      (PP due to
					  (NP its research outlays)))
				  ,
				  (VP giving
				      (NP a boost)
				      (PP-DTV to
					      (NP earnings))))))))
     ,
     (NP-SBJ she)
     (VP said
	 (SBAR 0
	       (S *T*-1)))
     .))
